← Clover Health Investments overview

Clover Health Investments vs Option Care Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Clover Health Investments Corp (CLOV)

Q3 2026
▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

  • Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.

    This regulatory win is a major new force behind CLOV's outlook and price.

  • Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.

    The profit swing and guidance raise are the clearest new evidence of improving finances.

  • Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.

    These operating drivers explain why results beat expectations and support the stock.

July 2026
▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

  • Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.

    This regulatory win is a major new force behind CLOV's outlook and price.

  • Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.

    The profit swing and guidance raise are the clearest new evidence of improving finances.

  • Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.

    These operating drivers explain why results beat expectations and support the stock.

Latest
▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

  • Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.

    This regulatory win is a major new force behind CLOV's outlook and price.

  • Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.

    The profit swing and guidance raise are the clearest new evidence of improving finances.

  • Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.

    These operating drivers explain why results beat expectations and support the stock.

Option Care Health Inc (OPCH)

Q3 2026
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

August 2026
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

Latest
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.